The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed novel treatment options for patients with hematologic malignancies.
This content originally appeared on our sister site, CancerNetwork®.
CancerNetwork® spoke with Julie Vose, MD, MBA, professor, internal medicine, division of oncology and hematology, University of Nebraska Medical Center, about novel options available for patients with hematologic malignancies at the 2021 American Society of Clinical Oncology Annual Meeting. She highlighted how these new options can work alone or potentially as part of a combination regimen in future treatment strategies.
The interesting aspects are looking at not only new drugs, new monoclonal antibodies, new CAR T-cells, [or] new bispecific antibodies. Looking at all these different modalities that can be utilized for all different types of hematologic malignancies, either alone or potentially in the future, combined together [is interesting]. We are going to have so many potential treatments that we will be able to [utilize to] help more patients and be able to get these new novel therapies to many more people.